Phase 1 N=12 Safety Study of Gene Therapy in Treating Critical Leg Ischemia
Critical Limb Ischemia
Primary: Treatment-Emergent Adverse Events. — 3; 3; 3; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
COVID-19
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs — 8; 2; 5; 6 Participants
Phase 1 N=15 A Phase I Study of TAS-102 in Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Cmax (Maximum Plasma Concentration) of FTD — 3019.49; 3693.08 ng/mL
N/A N=407 Safety Education in the Emergency Department: A Pilot Study
Firearm Injury
Primary: Acceptability of Intervention — 49; 104; 109; 13 Participants
N/A N=687 A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
Breast Cancer · Early Detection of Cancer
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of Thermalytix — 95.24; 88.58; 28.57; 99.74 percentage
N/A N=64 Breathing Retraining for Asthma Trial of Home Exercises for Teenagers
Adolescent Behavior · Asthma
Primary: Asthma-specific Quality of Life — 65.4; 65.1; 66.7; 67.4 score on a scale
Phase 1 N=12 MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
End-Stage Renal Disease · Kidney Failure, Chronic
Primary: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0 Participants
N/A N=22 Quit & Fit 2.0: Feasibility and Usability Testing
Smoking Cessation
Primary: Feasibility of the 6-week Tobacco Treatment Intervention — 14 Participants
Phase 1 N=112 Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Actinic Keratosis · Keratosis, Actinic · Keratosis
Primary: Frequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), and Treatment Emergent Adverse Events (TEAEs). — 888; 563; 242; 83 Number of events
Phase 3 N=141 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
Binge-Eating Disorder · Obesity
Primary: Binge-Eating Frequency — 2.95; 2.33; 0.96 Binge-eating episodes (past 28 days)
Phase 4 N=16 Identifying and Treating Depression in Hemodialysis Patients
Depression · Hemodialysis-Induced Symptom
Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale
N/A N=180 The FARAPULSE FARA-Freedom Trial
Paroxysmal Atrial Fibrillation
Primary: Effectiveness: Percentage of Participants Free of Chronic Treatment Failure Through 12 Months and Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial…
N/A N=20 Verify the Performance of the Neutral Electrode (NE) Adhesives
Adhesion of the Neutral Electrode 21pad
Primary: Number of Tests With No More Than 5% Separation - Neutral Electrode (NE) Adhesive Separation — 39 Tests
Phase 2 N=58 Effect of Galantamine on Inflammation and Cognition
HIV Associated Cognitive Motor Complex
Primary: Change in Cognition — .018; .12; 0.068; 0.201 Z-score
N/A N=30 Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe
Bronchi--Diseases · Lung Diseases, Obstructive · Lesions Mass
Primary: Ability to Successfully Obtain Sample — 123; 130 tissue samples